keyword
MENU ▼
Read by QxMD icon Read
search

subtype parkinson's disease

keyword
https://www.readbyqxmd.com/read/28102045/inflammatory-profile-discriminates-clinical-subtypes-in-lrrk2-associated-parkinson-s-disease
#1
K Brockmann, C Schulte, N Schneiderhan-Marra, A Apel, C Pont-Sunyer, D Vilas, J Ruiz-Martinez, M Langkamp, J-C Corvol, F Cormier, T Knorpp, T O Joos, A Bernard, T Gasser, C Marras, B Schüle, J O Aasly, T Foroud, J F Marti-Masso, A Brice, E Tolosa, D Berg, W Maetzler
BACKGROUND AND PURPOSE: The presentation of Parkinson's disease patients with mutations in the LRRK2 gene (PDLRRK2 ) is highly variable, suggesting a strong influence of modifying factors. In this context, inflammation is a potential candidate inducing clinical subtypes. METHODS: An extensive battery of peripheral inflammatory markers was measured in human serum in a multicentre cohort of 142 PDLRRK2 patients from the MJFF LRRK2 Consortium, stratified by three different subtypes as recently proposed for idiopathic Parkinson's disease: diffuse/malignant, intermediate and mainly pure motor...
February 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28099414/neurotoxic-reactive-astrocytes-are-induced-by-activated-microglia
#2
Shane A Liddelow, Kevin A Guttenplan, Laura E Clarke, Frederick C Bennett, Christopher J Bohlen, Lucas Schirmer, Mariko L Bennett, Alexandra E Münch, Won-Suk Chung, Todd C Peterson, Daniel K Wilton, Arnaud Frouin, Brooke A Napier, Nikhil Panicker, Manoj Kumar, Marion S Buckwalter, David H Rowitch, Valina L Dawson, Ted M Dawson, Beth Stevens, Ben A Barres
Reactive astrocytes are strongly induced by central nervous system (CNS) injury and disease, but their role is poorly understood. Here we show that a subtype of reactive astrocytes, which we termed A1, is induced by classically activated neuroinflammatory microglia. We show that activated microglia induce A1 astrocytes by secreting Il-1α, TNF and C1q, and that these cytokines together are necessary and sufficient to induce A1 astrocytes. A1 astrocytes lose the ability to promote neuronal survival, outgrowth, synaptogenesis and phagocytosis, and induce the death of neurons and oligodendrocytes...
January 18, 2017: Nature
https://www.readbyqxmd.com/read/28094017/predictive-markers-guide-differentiation-to-improve-graft-outcome-in-clinical-translation-of-hesc-based-therapy-for-parkinson-s-disease
#3
Agnete Kirkeby, Sara Nolbrant, Katarina Tiklova, Andreas Heuer, Nigel Kee, Tiago Cardoso, Daniella Rylander Ottosson, Mariah J Lelos, Pedro Rifes, Stephen B Dunnett, Shane Grealish, Thomas Perlmann, Malin Parmar
Stem cell treatments for neurodegenerative diseases are expected to reach clinical trials soon. Most of the approaches currently under development involve transplantation of immature progenitors that subsequently undergo phenotypic and functional maturation in vivo, and predicting the long-term graft outcome already at the progenitor stage remains a challenge. Here, we took an unbiased approach to identify predictive markers expressed in dopamine neuron progenitors that correlate with graft outcome in an animal model of Parkinson's disease through gene expression analysis of >30 batches of grafted human embryonic stem cell (hESC)-derived progenitors...
January 5, 2017: Cell Stem Cell
https://www.readbyqxmd.com/read/28089265/gender-differences-in-parkinson-s-disease-depression
#4
Andrew J Perrin, Ekaterina Nosova, Kim Co, Adam Book, Oscar Iu, Vanessa Silva, Christina Thompson, Martin J McKeown, A Jon Stoessl, Matthew J Farrer, Silke Appel-Cresswell
INTRODUCTION: 30-40% of patients with Parkinson's disease (PD) experience depression during their illness; identifying subtypes of depression and groups at risk remains a challenge in routine clinical care. One avenue that remains underexplored is the gender-specific profiles manifested in PD depression. We sought to explore this in a large sample of clinical PD patients. METHODS: 307 patient records at a tertiary referral centre were reviewed for clinical and demographic factors...
December 29, 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28078311/common-variant-rs356182-near-snca-defines-a-parkinson-s-disease-endophenotype
#5
Christine A Cooper, Nimansha Jain, Michael D Gallagher, Daniel Weintraub, Sharon X Xie, Yosef Berlyand, Alberto J Espay, Joseph Quinn, Karen L Edwards, Thomas Montine, Vivianna M Van Deerlin, John Trojanowski, Cyrus P Zabetian, Alice S Chen-Plotkin
OBJECTIVE: Parkinson's disease (PD) presents clinically with several motor subtypes that exhibit variable treatment response and prognosis. Here, we investigated genetic variants for their potential association with PD motor phenotype and progression. METHODS: We screened 10 SNPs, previously associated with PD risk, for association with tremor-dominant (TD) versus postural-instability gait disorder (PIGD) motor subtypes. SNPs that correlated with the TD/PIGD ratio in a discovery cohort of 251 PD patients were then evaluated in a multi-site replication cohort of 559 PD patients...
January 2017: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/28062949/can-cyclic-nucleotide-phosphodiesterase-inhibitors-be-drugs-for-parkinson-s-disease
#6
REVIEW
Dominic Ngima Nthenge-Ngumbau, Kochupurackal P Mohanakumar
Parkinson's disease (PD) has no known cure; available therapies are only capable of offering temporary, symptomatic relief to the patients. Varied therapeutic strategies that are clinically used for PD are pharmacological therapies including dopamine replacement therapies (with or without adjuvant), postsynaptic dopamine receptor stimulation, dopamine catabolism inhibitors and also anticholinergics. Surgical therapies like deep brain stimulation and ablative surgical techniques are also employed. Phosphodiesterases (PDEs) are enzymes that degrade the phosphodiester bond in the second messenger molecules, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP)...
January 6, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28056455/the-association-of-musculoskeletal-pain-with-bone-mineral-density-in-patients-with-parkinson-s-disease
#7
Seong-Min Choi, Byeong C Kim, Hyun-Jung Jung, Geum-Jin Yoon, Kyung Wook Kang, Kang-Ho Choi, Seung-Han Lee, Man-Seok Park, Myeong-Kyu Kim, Ki-Hyun Cho
BACKGROUND: Pain and osteoporosis are common in Parkinson's disease (PD), and lower bone mineral density (BMD) or osteoporosis may be associated with an increased risk of reporting to have pain in the general population. The aim of this study was to determine whether there is an association between the pain subtypes and the BMD in patients with PD. METHODS: We included 162 PD patients. Pain was assessed using the patients' descriptions, a structured interview, a detailed neurologic examination, and the Visual Analogue Scale...
January 5, 2017: European Neurology
https://www.readbyqxmd.com/read/28035410/inhibiting-purinergic-p2x7-receptors-with-the-antagonist-brilliant-blue-g-is-neuroprotective-in-an-intranigral-lipopolysaccharide-animal-model-of-parkinson-s-disease
#8
Xin-Hong Wang, Xin Xie, Xiao-Guang Luo, Hong Shang, Zhi-Yi He
Parkinson's disease (PD) is a common neurodegenerative disorder, which is characterized by the selective and progressive death of dopaminergic (DA) neurons in the substantia nigra. Increasing evidence suggests that inflammation is important in the degeneration of DA neurons. The purinergic receptor subtype P2X7 receptor (P2X7R) is key in the activation and proliferation of microglia. The present study aimed to examine whether inhibiting purinergic P2X7 receptors is neuroprotective in a rat model of PD, specifically via inhibiting p38 mitogen‑activated protein kinase (MAPK)...
February 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28034996/a-fully-automated-atlas-based-approach-for-superior-cerebellar-peduncle-evaluation-in-progressive-supranuclear-palsy-phenotypes
#9
G Nicoletti, M E Caligiuri, A Cherubini, M Morelli, F Novellino, G Arabia, M Salsone, A Quattrone
BACKGROUND AND PURPOSE: The superior cerebellar peduncle is damaged in progressive supranuclear palsy. However, alterations differ between progressive supranuclear palsy with Richardson syndrome and progressive supranuclear palsy-parkinsonism. In this study, we propose an automated tool for superior cerebellar peduncle integrity assessment and test its performance in patients with progressive supranuclear palsy with Richardson syndrome, progressive supranuclear palsy-parkinsonism, Parkinson disease, and healthy controls...
December 29, 2016: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28031995/prevalence-of-progressive-supranuclear-palsy-in-yonago-change-throughout-a-decade
#10
Hiroshi Takigawa, Michio Kitayama, Kenji Wada-Isoe, Hisanori Kowa, Kenji Nakashima
BACKGROUND: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder that is sometimes confused with Parkinson's disease, multiple system atrophy, and other disorders. The typical clinical features are categorized as Richardson's syndrome (RS), but other clinical subtypes include PSP-parkinsonism (PSP-P) and PSP-pure akinesia with gait freezing (PSP-PAGF). In this study, we determined the prevalence of PSP in a Japanese rural area compared to our previous 1999 report. METHODS: We collected data in Yonago City from 2009 to 2014 using a service-based study of PSP...
December 2016: Brain and Behavior
https://www.readbyqxmd.com/read/28028643/parkinson-s-a-syndrome-rather-than-a-disease
#11
REVIEW
Nataliya Titova, C Padmakumar, Simon J G Lewis, K Ray Chaudhuri
Emerging concepts suggest that a multitude of pathology ranging from misfolding of alpha-synuclein to neuroinflammation, mitochondrial dysfunction, and neurotransmitter driven alteration of brain neuronal networks lead to a syndrome that is commonly known as Parkinson's disease. The complex underlying pathology which may involve degeneration of non-dopaminergic pathways leads to the expression of a range of non-motor symptoms from the prodromal stage of Parkinson's to the palliative stage. Non-motor clinical subtypes, cognitive and non-cognitive, have now been proposed paving the way for possible subtype specific and non-motor treatments, a key unmet need currently...
December 27, 2016: Journal of Neural Transmission
https://www.readbyqxmd.com/read/28017247/clinical-characteristics-of-parkinsonism-in-frontotemporal-dementia-according-to-subtypes
#12
Hee Kyung Park, Kee Hyung Park, Bora Yoon, Jae-Hong Lee, Seong Hye Choi, Jee H Joung, Soo Jin Yoon, Byeong C Kim, Seung Hyun Kim, Eun-Joo Kim, Duk L Na, Kyung Won Park
BACKGROUND: We investigated the prevalence of parkinsonism in frontotemporal dementia (FTD) subtypes and the cognitive and behavioral differences between FTD with and without parkinsonism in a well-structured, prospective cohort. METHODS: One hundred and ninety-one FTD patients were enrolled and all patients underwent comprehensive neurological evaluations, neuropsychological tests, and the Unified Parkinson's Disease Rating Scale. RESULTS: The prevalence of parkinsonism was 38...
January 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28012952/frontotemporal-dementia-as-the-presenting-phenotype-of-p-a53t-mutation-carriers-in-the-alpha-synuclein-gene
#13
Anastasia Bougea, Christos Koros, Maria Stamelou, Athina Simitsi, Nikolaos Papagiannakis, Roubina Antonelou, Dimitra Papadimitriou, Marianthi Breza, Konstantinos Tasios, Stella Fragkiadaki, Xenia Geronicola Trapali, Mara Bourbouli, Georgios Koutsis, Sokratis G Papageorgiou, Elisabeth Kapaki, George P Paraskevas, Leonidas Stefanis
INTRODUCTION: The p.A53T point mutation in SNCA, the alpha-synuclein gene, has been linked to a rare dominant form of Parkinson's disease (PD). METHODS: Here, we describe two apparently unrelated cases of p.A53T (G209A) SNCA mutation carriers with an atypical initial manifestation and disease course. Moreover, cerebrospinal fluid (CSF) levels of tau, p-tau and amyloid Aβ42 were measured in these patients and in an additional cohort of 5 symptomatic and 2 asymptomatic p...
December 6, 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28007517/re-emergent-tremor-in-parkinson-s-disease
#14
Daniele Belvisi, Antonella Conte, Matteo Bologna, Maria Carmela Bloise, Antonio Suppa, Alessandra Formica, Matteo Costanzo, Pierluigi Cardone, Giovanni Fabbrini, Alfredo Berardelli
INTRODUCTION: Re-emergent tremor (RET) is a postural tremor that appears after a variable delay in patients with Parkinson's disease (PD). The aim of the present study was to evaluate the occurrence and the clinical characteristics of RET in a population of patients with PD. METHODS: We consecutively assessed 210 patients with PD. We collected the patients' demographic and clinical data. RET was clinically characterized in terms of latency, severity and body side affected...
December 16, 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28004201/autonomic-disturbances-including-impaired-hand-thermoregulation-in-multiple-system-atrophy-and-parkinson-s-disease
#15
Sarunas Augustis, Viktoras Saferis, Wolfgang H Jost
Autonomic dysfunction in multiple system atrophy (MSA) comprises cardinal symptoms of orthostatic hypotension (OH) and urinary incontinence. Additionally, cardiovagal and sudomotor abnormalities can be present. Previous studies compared hand skin temperature and its response to cooling in subjects with probable MSA and Parkinson's disease (PD). Significant differences were found indicating that disturbed thermoregulation belongs to MSA autonomic features and could be helpful in differentiation of MSA from PD...
December 21, 2016: Journal of Neural Transmission
https://www.readbyqxmd.com/read/27993708/subtypes-evaluation-of-motor-dysfunction-in-parkinson-s-disease-using-neuromelanin-sensitive-magnetic-resonance-imaging
#16
Yuanyuan Xiang, Tao Gong, Junwei Wu, Jifeng Li, Yan Chen, Yongxiang Wang, Shan Li, Lin Cong, Youting Lin, Yuxiang Han, Ling Yin, Guangbin Wang, Yifeng Du
Parkinson's disease (PD) is characterized by the loss of neuromelanin (NM)-containing neurons in the substantia nigra pars compacta (SNc), and it is divided into two motor subtypes: the postural instability gait difficulty (PIGD) and the tremor dominant (TD) subtypes. With NM-sensitive Magnetic Resonance Imaging (NM-MRI), investigators have been able to accurately detect signal attenuation in SNc of PD; however, the difference of NM loss between PIGD and TD subtypes is still unclear. Thus, the aim of this study was to evaluate the differences in NM-MRI between PD motor subtypes...
December 16, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/27993522/non-motor-symptoms-and-the-quality-of-life-in-multiple-system-atrophy-with-different-subtypes
#17
LingYu Zhang, Bei Cao, RuWei Ou, Qian-Qian Wei, Bi Zhao, Jing Yang, Ying Wu, HuiFang Shang
BACKGROUND: The differences in non-motor symptoms (NMS) and quality of life (QOL) between MSA patients with different subtypes remain unknown, so do the determinants of poor QOL in both subtypes. METHODS: A total of 172 MSA patients were enrolled in the study. NMS of patients with MSA were assessed using the non-motor symptoms scale (NMSS) and Parkinson's Disease Questionnaire-39 item version (PDQ-39) was used to evaluate the QOL of patients with MSA. RESULTS: The most prevalent NMS domain was urinary (91...
December 13, 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/27986876/changes-in-insomnia-subtypes-in-early-parkinson-disease
#18
Lena K Tholfsen, Jan P Larsen, Jörn Schulz, Ole-Bjørn Tysnes, Michaela D Gjerstad
OBJECTIVE: To examine the development of factors associated with insomnia in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis. METHODS: One hundred eighty-two drug-naive patients with PD derived from a population-based incident cohort and 202 control participants were assessed for insomnia before treatment initiation and were repeatedly examined after 1, 3, and 5 years. Insomnia was diagnosed according to the Stavanger Sleepiness Questionnaire...
December 16, 2016: Neurology
https://www.readbyqxmd.com/read/27984197/chronic-nicotine-treatment-decreases-lps-signaling-through-nf-%C3%AE%C2%BAb-and-tlr-4-modulation-in-the-hippocampus
#19
Cecília Cerqueira Café-Mendes, Humberto Miguel Garay-Malpartida, Marília Brinati Malta, Cristóforo Scavone, Zulma S Ferreira, Regina P Markus, Tania Marcourakis
The hippocampus is a brain region that is rich in nicotinic acetylcholine receptors (nAChRs), especially the α7 subtype. The hippocampus is severely affected in disorders that have a neuroinflammatory component, such as Alzheimer's disease, Parkinson's disease, and schizophrenia. Previous studies demonstrated both in vivo and in vitro that nicotine inhibits immunological responses, including those that are triggered by the inflammatory agent lipopolysaccharide (LPS), the endotoxin of Gram-negative bacteria...
October 28, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/27979722/apomorphine-pharmacological-properties-and-clinical-trials-in-parkinson-s-disease
#20
Peter Jenner, Regina Katzenschlager
Apomorphine is often considered an archetypal dopamine agonist used in the treatment of Parkinson's disease (PD). However, it can be clearly differentiated from most other commonly used dopamine agonists on the basis of its pharmacology and on its unique clinical profile. Like levodopa and dopamine, apomorphine acts as a potent, direct and broad spectrum dopamine agonist activating all dopamine receptor subtypes. It also has affinity for serotonin receptors, and α-adrenergic receptors. Apomorphine is usually titrated to a dose that provides an equivalent antiparkinsonian response to that provided by levodopa, and its subcutaneous delivery allows a rapid onset of action, usually within 7-10 min...
December 2016: Parkinsonism & related Disorders
keyword
keyword
39250
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"